Furthermore, our findings are highly relevant with the above-mentioned clinical trials investigating FGF-21 analogs for the treatment of NASH, as mentioned above, especially in the light of potential FGF-21 resistance or insensitivity observed in advanced disease. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.